Interim Assessment of Kidney Dosimetry and Pharmacokinetics in a Phase I Study of CTT1403, a novel 177Lu-labeled Small Molecule Inhibitor of Prostate Specific Membrane Antigen

Conclusions: We demonstrated the feasibility of estimating radiation doses in kidneys using quantitative 177Lu-SPECT/CT for CTT1403 therapy. The absorbed dose in kidneys in the first 6 subjects was well below the threshold of 23 Gy, considered the dose limiting exposure level[SY1] [BL2] . The elimination phase half-life of CTT1403 showed prolonged retention in blood plasma for this small molecule peptidomimetic, confirming enhanced circulation time imparted by the albumin binding component. Acknowledgements: The study was supported by the National Institutes of Health under grant R44CA239461, and Cancer Targeted Technology, LLC.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Seo, Y., Huh, Y., Murthy, V., Windish, H., Langton-Webster, B., Blecha, J., VanBrocklin, H., Behr, S., Aggarwal, R. Tags: Prostate: PSMA radioligand therapy Source Type: research